Singapore Periodontal Therapeutics Market Analysis

Singapore Periodontal Therapeutics Market Executive Summary

Singapore Periodontal Therapeutics Market is at around $1.1 Mn in 2023 and is projected to reach $1.8 Mn in 2030, exhibiting a CAGR of 7.8% during the forecast period.

Periodontal disease, another name for gum disease, is a serious dental condition linked to gum infection and inflammation. It envelops the teeth. Commonly brought on by poor oral hygiene, periodontitis is mostly preventable with therapeutic, non-surgical, or surgical treatment options. Periodontal therapy, a relatively new but effective therapeutic approach that is gaining Favor with patients and dentists, is the use of antibiotics alone to treat periodontitis. In periodontal therapy, antibiotics like as doxycycline, amoxicillin, and metronidazole are commonly utilized. A range of mouthwashes and rinses with antimicrobial ingredients such as hydrogen peroxide, chlorhexidine, and essential oils are adjunctive therapy for lowering gingival inflammation and plaque.

The prevalence of periodontal disease in Singapore is estimated to be around 50-60% among adults, with severe periodontitis affecting approximately 10-15% of the population. Key demographic factors influencing periodontal health include age, with higher prevalence in older adults, and socioeconomic status, as lower-income groups tend to have poorer oral health. Smoking and diabetes are also significant risk factors. Healthcare expenses related to periodontal treatment in Singapore can vary widely, ranging from SGD 100-500 for basic scaling and root planning to several thousand dollars for advanced surgical procedures. The growing awareness of oral health and an aging population are likely to increase the demand for periodontal care, potentially driving up healthcare costs in this sector. This market is expected to expand due to ongoing innovations and a focus on comprehensive dental care. Therefore, the market is driven by significant factors like Aging population, Rise in Demand for Non-surgical Periodontal Therapies, and Prevalence of periodontitis. However, Regulatory Complications, Side Effects, and Cost of treatment restrict the growth and potential of the market.

AMD Lasers announced the development of the Monet™ laser curing light, the first handheld laser in curing light for dental materials.

Market Dynamics

Market Growth Drivers

Aging population: Residents aged 65 years and above made up 16.6% of the total resident population in Singapore. As people age, they become more susceptible to periodontal diseases due to factors like reduced immune function, medication side effects, and cumulative damage to gum tissues over time. This demographic shift is likely to drive higher demand for periodontal treatments and therapies. Older adults often require more frequent dental check-ups and interventions to maintain oral health, including treatments for gum diseases.

Rise in Demand for Non-surgical Periodontal Therapies: Demand for non-surgical treatments for periodontal diseases has increased significantly in the past few years. The treatments include periodontal scaling & root planning and the usage of antibiotics, especially in severe forms of periodontal disease. Advances in pharmacologic therapies are expected to create significant opportunities for companies in the market in the next few years.

Prevalence of periodontitis: Periodontal disease continues to affect a significant portion of the population, with a prevalence rate of 50% in adults. This high prevalence drives demand for diagnostic tools, treatments, and preventive measures. Increasing awareness of oral health's systemic impact prompts more individuals to seek professional dental care, bolstering the market for periodontal therapies, dental implants, and regenerative treatments. Advances in technology and better healthcare access contribute to market growth.

Market Restraints

Regulatory Complications: Singapore faces regulatory challenges such as strict licensing requirements for dental professionals, leading to a shortage of specialized periodontists. High operational costs due to stringent healthcare standards and stringent import regulations on medical devices increase the overall cost of periodontal treatments. Limited government subsidies for dental care also deter patients from seeking timely periodontal interventions, affecting market demand and growth.

Side Effects: Certain periodontal therapies, particularly invasive surgical procedures, and some pharmacological treatments, can have potential side effects and complications. These may include infection, swelling, pain, and adverse reactions to medications. The fear of these possible side effects can deter patients from seeking treatment. Moreover, negative experiences or outcomes from treatment can lead to reduced trust and reluctance to pursue further periodontal care, impacting the overall market demand.

Cost of treatment: The advanced and specialized nature of periodontal treatments leads to higher costs, making them inaccessible for a significant portion of the population. Private healthcare dominance results in limited affordability options, with out-of-pocket expenses for periodontal procedures often deterring potential patients. In fact, up to 70% of individuals in some regions face financial barriers that prevent them from accessing these treatments. This financial barrier hampers market expansion, despite growing awareness and demand for dental care.

Regulatory Landscape and Reimbursement scenario

Singapore's periodontics market is regulated under the country's broader healthcare framework, primarily overseen by the Ministry of Health (MOH) and the Singapore Dental Council (SDC). Dental practitioners, including periodontists, must be registered with the SDC and adhere to strict professional standards and ethical guidelines. The Private Hospitals and Medical Clinics Act governs dental clinics, ensuring they meet safety and quality standards. Medical devices and drugs used in periodontal treatments are regulated by the Health Sciences Authority (HSA). The government promotes continuing education for dental professionals and emphasizes preventive care. Singapore's regulatory environment aims to maintain high standards of dental care while fostering innovation and ensuring patient safety in the periodontics market.

In Singapore's periodontal market, reimbursement for dental procedures is primarily managed through a combination of government subsidies and private insurance. The Community Health Assist Scheme (CHAS) provides subsidies for lower- to middle-income Singaporeans at participating dental clinics. MediSave, a national medical savings scheme, can be used for certain complex dental procedures. Private dental insurance plans offer varying levels of coverage for periodontal treatments. However, many Singaporeans still pay out-of-pocket for routine dental care and non-surgical periodontal treatments. The government encourages preventive care through public health initiatives, which may indirectly impact reimbursement patterns by reducing the need for costly interventions. Overall, the reimbursement landscape in Singapore's periodontal market balances public assistance with individual responsibility.

Competitive Landscape

Key Players

Here are some of the major key players in Singapore Periodontal Therapeutics Market:

• Pfizer Inc.
• Lupin Ltd
• Teva Pharmaceuticals USA, Inc.
• Sun Pharmaceutical Industries Ltd.
• Tokyo Chemical Industry Co., Ltd.
• Bausch Health Companies Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Chartwell Pharmaceuticals LLC.
• ASA Dental S.p.A.
• Steris-Hu-Friedy
• Carl Martin GmBH